UPDATE: Bank of America Raises PT on Durata Therapeutics after Positive Phase 3 Trial Data

In a report published Monday, Bank of America reiterated its Buy rating on Durata Therapeutics DRTX, and raised its price target from $12.00 to $14.00. Bank of America noted, “DRTX reported top-line data from its second pivotal phase 3 trial, DISCOVER-2, for dalbavancin in abSSSI. The early response rate at 48-72 hours (FDA primary endpoint) was 77% in the dalbavancin arm vs. 78% in the vancomycin/ linezolid arm and within a 10% non-inferiority margin. With positive data from both phase 3 trials, DRTX is on track to file with the FDA and EMA by mid-year and YE 2013, respectively. We increased our US and EMA probability of approvals to 80% (from 65%) and to 75% (from 55%), raising our DCF-derived PO by $2, to $14. We were previously cautious about EU approval, as DISCOVER-1 data just met the EMA primary endpoint, but DISCOVER-2 data were more favorable. Dalba's designation as a QIDP should result in a 6-8 month FDA review period.” Durata Therapeutics closed on Friday at $7.60.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorPrice TargetAnalyst RatingsBank of America
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!